Literature DB >> 7150251

The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids.

P Binek-Singer, T C Johnson.   

Abstract

A prolonged elevation in the concentrations of circulating phenylalanine was maintained in newborn mice by daily injections of phenylalanine and a phenylalanine hydroxylase inhibitor, alpha-methylphenylalanine. The result of this chronic hyperphenylalaninaemia was an accumulation of vacant or inactive monoribosomes that persisted for 18 h of each day. An elongation assay in vitro with brain postmitochondrial supernatants demonstrated that, in addition, there was an equally prolonged decrease in the rates of polypeptide-chain elongation by the remaining brain polyribosomes. Analyses of the free amino acid composition in the brains of hyperphenylalaninaemic mice showed a loss of several amino acids from the brain, particularly the large, neutral amino acids, which are co- or counter-transported across plasma membranes with phenylalanine. When a mixture of these amino acids (leucine, isoleucine, valine, threonine, tryptophan, tyrosine, methionine) was injected into hyperphenylalaninaemic mice, there was an immediate cessation of monoribosome accumulation in the brain and there was no inhibition of the rates of polypeptide-chain elongation. Although the concentrations of the large, neutral amino acids in the brain were partially preserved by treatment of hyperphenylalaninaemic mice with the amino acid mixture, the elevated concentrations of phenylalanine remained unaltered. The amino acid mixture had no detectable effect on brain protein synthesis in the absence of the hyperphenylalaninaemic condition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150251      PMCID: PMC1158598          DOI: 10.1042/bj2060407

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  Role of ribonuclease action in phenylalanine-induced disaggregation of rat cerebral polyribosomes.

Authors:  S Roberts; B S Morelos
Journal:  J Neurochem       Date:  1976-02       Impact factor: 5.372

2.  The mechanism of polyribosome disaggregation in brain tissue by phenylalanine.

Authors:  F Taub; T C Johnson
Journal:  Biochem J       Date:  1975-10       Impact factor: 3.857

3.  Studies on the structure of ribosomes. IV. Participation of aminoacyl-transfer RNA and peptidyl-transfer RNA in the association of ribosomal subparticles.

Authors:  N V Belitsina; A S Spirin
Journal:  J Mol Biol       Date:  1970-08-28       Impact factor: 5.469

4.  Thermal stability of poly(U)-tRNA-ribosome complexes with Phe-tRNA Phe and peptidyl-tRNA Phe .

Authors:  A D Hamburger; Y Lapidot; N De Groot
Journal:  Eur J Biochem       Date:  1973-02-01

5.  The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain.

Authors:  C M McKean; D E Boggs; N A Peterson
Journal:  J Neurochem       Date:  1968-03       Impact factor: 5.372

6.  Resistance of active yeast ribosomes to dissociation by KCl.

Authors:  T E Martin; L H Hartwell
Journal:  J Biol Chem       Date:  1970-03-25       Impact factor: 5.157

7.  Hyperphenylalaninemia: disaggregation of brain polyribosomes in young rats.

Authors:  K Aoki; F L Siegel
Journal:  Science       Date:  1970-04-03       Impact factor: 47.728

8.  Effects of excess phenylalanine on in vitro and in vivo RNA and protein synthesis and polyribosome levels in brains of mice.

Authors:  J W MacInnes; K Schlesinger
Journal:  Brain Res       Date:  1971-06-04       Impact factor: 3.252

9.  Polyribosome disaggregation and cell-free protein synthesis in preparations from cerebral cortex of hyperphenylalaninemic rats.

Authors:  F L Siegel; K Aoki; R E Colwell
Journal:  J Neurochem       Date:  1971-04       Impact factor: 5.372

10.  Tolerance of protein and lipid synthesis to mild hyperphenylalaninemia in developing rat brain.

Authors:  R L Geison; F L Siegel
Journal:  Brain Res       Date:  1975-07-18       Impact factor: 3.252

View more
  9 in total

Review 1.  Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids.

Authors:  W M Pardridge
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

2.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Cerebral protein synthesis in a genetic mouse model of phenylketonuria.

Authors:  C B Smith; J Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 4.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

5.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

6.  The effect of elevated plasma phenylalanine levels on protein synthesis rates in adult rat brain.

Authors:  D S Dunlop; X R Yang; A Lajtha
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

Review 7.  Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria.

Authors: 
Journal:  BMJ       Date:  1993-01-09

Review 8.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

9.  Post-Translational Incorporation of L-Phenylalanine into the C-Terminus of α-Tubulin as a Possible Cause of Neuronal Dysfunction.

Authors:  Yanina Ditamo; Yanela M Dentesano; Silvia A Purro; Carlos A Arce; C Gastón Bisig
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.